Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy.
Pinho MB, Costas F, Sellos J, Dienstmann R, Andrade PB, Herchenhorn D, Peixoto FA, Santos VO, Small IA, Guimarães DP, Ferreira CG. Pinho MB, et al. Among authors: ferreira cg. Urol Oncol. 2009 Jul-Aug;27(4):382-90. doi: 10.1016/j.urolonc.2008.03.016. Epub 2008 Jun 16. Urol Oncol. 2009. PMID: 18555708 Clinical Trial.
Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Araujo LH, Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC. Zukin M, et al. Among authors: ferreira cg. J Clin Oncol. 2013 Aug 10;31(23):2849-53. doi: 10.1200/JCO.2012.48.1911. Epub 2013 Jun 17. J Clin Oncol. 2013. PMID: 23775961 Clinical Trial.
Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC, Karen de Sá V, Sternberg C, Olivieri ER, Werneck da Cunha I, Fabro AT, Carraro DM, de Barros e Silva MJ, Pimenta Inada HK, de Mello ES, Soares FA, Takagaki T, Ferreira CG, Capelozzi VL. de Melo AC, et al. Among authors: ferreira cg. Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1. Oncology. 2015. PMID: 25833149
Lung cancer in Brazil.
Araujo LH, Baldotto C, Castro G Jr, Katz A, Ferreira CG, Mathias C, Mascarenhas E, Lopes GL, Carvalho H, Tabacof J, Martínez-Mesa J, Viana LS, Cruz MS, Zukin M, Marchi P, Terra RM, Ribeiro RA, Lima VCC, Werutsky G, Barrios CH; Grupo Brasileiro de Oncologia Torácica. Araujo LH, et al. Among authors: ferreira cg. J Bras Pneumol. 2018 Jan-Feb;44(1):55-64. doi: 10.1590/S1806-37562017000000135. J Bras Pneumol. 2018. PMID: 29538545 Free PMC article. Review.
Increasing access to next-generation sequencing in oncology for Brazil.
Santos M, Coudry RA, Ferreira CG, Stefani S, Cunha IW, Zalis MG, Araujo LH. Santos M, et al. Among authors: ferreira cg. Lancet Oncol. 2019 Jan;20(1):20-23. doi: 10.1016/S1470-2045(18)30822-2. Lancet Oncol. 2019. PMID: 30614460 No abstract available.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
169 results